Physician profile
Savneek S Chugh
NPI 1851622476
$324,814.83
in general payments reported to CMS, 2019-2025
13 companies · $67K in 2025
The $67K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56K · 2020: $18K · 2021: $16K · 2022: $38K · 2023: $94K · 2024: $36K · 2025: $67K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $145K · Consulting Fee: $30K · Travel and Lodging: $12K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $5,119 · Food and Beverage: $3,799 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $145,290.00 |
| Consulting Fee | $30,179.86 |
| Travel and Lodging | $12,277.80 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $5,118.50 |
| Food and Beverage | $3,798.79 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $301,884.87 | 2019-2025 | Ultomiris, Strensiq |
| Apellis Pharmaceuticals, INC. | $15,055.33 | 2025 | Empaveli |
| Travere Therapeutics, INC. | $3,846.32 | 2019-2023 | |
| Vifor Pharma, INC. | $1,938.49 | 2020 | |
| Calliditas Therapeutics US INC. | $1,279.77 | 2023 | Tarpeyo |
| Vertex Pharmaceuticals Incorporated | $270.83 | 2021 | |
| Glaxosmithkline, LLC. | $200.00 | 2023 | Benlysta |
| Genentech USA, INC. | $123.44 | 2019 | |
| Akcea Therapeutics, INC. | $116.80 | 2019 | |
| Amgen INC. | $34.78 | 2020 | |
| Aurinia Pharma U.S., INC. | $28.10 | 2023 | Lupkynis |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.98 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $16.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Savneek Chugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.